x Acta Scientific | International Open Library | Open Access Journals Publishing Group

Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Editorial Volume 4 Issue 11

Pathogenesis, Epidemiology, and Clinical Features among SARS-CoV-2 and Associated Diseases: An Editorial

Abhishek Kumar Verma1*, Abhishek Dadhich2, Anisha Choudhary2 and Prakhar Bhardwaj2

1Assistant Professor, Department of Life Sciences, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
2Research Scholar, Department of Plant Sciences, Central University of Punjab, Bathinda, Punjab, India

*Corresponding Author: Abhishek Kumar Verma, Assistant Professor, Department of Life Sciences, Mewar University, Gangrar, Chittorgarh, Rajasthan, India.

Received: September 22, 2020; Published: September 30, 2020


  A new human coronavirus virus emerged in Wuhan, the city of China in December 2019 named novel coronavirus (SARS-CoV-2). Currently, this coronavirus becomes a pandemic and affects most of the countries worldwide. Presently (as of 3 June 2020) 6287771 confirmed cases and 379941 deaths have been reported globally according to WHO data [1]. The clinical syndrome of coronavirus associated with SARS-CoV-2 infection; is categorized by respiratory illness ranging from upper respiratory tract from the common cold to fatal pneumonia and severe acute respiratory distress syndrome (ARDS) [2].



  1. Chen L Han, Yang F, Zhang tJ (2001).
  2. World Health Organization. “Coronavirus disease 2019 (COVID-19) situation report-48”. 08th March. (2020).
  3. Munster VJ., et al. “A novel coronavirus emerging in China-key questions for impact assessment”. New England Journal of Medicine8 (2020): 692-694.
  4. Teleman MD., et al. “Factors associated with the transmission of the severe acute respiratory syndrome among health-care workers in Singapore”. Epidemiology and amp Infection5 (2004): 797-803.
  5. Quot COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) and quot; ArcGIS”. Johns Hopkins University (2020).
  6. Old age, sepsis tied to poor COVID-19 outcomes, death and quot; CIDRAP, University of Minnesota (2020).
  7. Karlberg J., et al. “Do men have a higher case fatality rate of a severe acute respiratory syndrome than women do?” American Journal of Epidemiology3 (2004): 229-231.
  8. Lippi G., et al. “Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis”. Progress in Cardiovascular Diseases (2020).
  9. World Health Organization. Infection prevention and control of epidemic- and pandemic- prone acute respiratory infections in health care. Geneva: World Health Organization (2014).
  10. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) 16-24 (2020).
  11. Ong SWX., et al. “Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from the asymptomatic patient”. The Journal of the American Medical Association16 (2020): 1610-1612.
  12. World Health Organization. “Modes of transmission of the virus causing COVID-19: implications for IPC precaution recommendations: scientific brief (2020).
  13. Law S., et al. “Severe acute respiratory syndrome (SARS) and coronavirus disease-2019 (COVID-19): From causes to preventions in Hong Kong”. International Journal of Infectious Diseases (2020).
  14. Medscape Drugs and amp; Diseases: emedicine. medscape.
  15. Centers for Disease Control and Prevention: Symptoms and Testing.
  16. Centers for Disease Control and Prevention: People Who Are at Higher Risk for Severe Illness.
  17. Beers M., et al. “Acute hypoxemic respiratory failure (AHRF, ARDS). Merck manual of diagnosis and therapy”. 18th New Jersey: Merck Research Lab (2006).
  18. Symptoms, Diagnosis and Monitoring of Arrhythmia.
  19. Overview of Arrhythmias.
  20. Broken heart syndrome.
  21. Overview of Cardiomyopathies.
  22. Pulmonary Embolism (PE).
  23. Pulmonary embolism.
  24. Pulmonary embolism.
  25. Disseminated Intravascular Coagulation (DIC).
  26. Guillain-Barré Syndrome (GBS).
  27. Singer M., et al. “The third international consensus definitions for sepsis and septic shock (sepsis-3)”. The Journal of the American Medical Association 315 (2016): 801-810.
  28. Sepsis and Septic Shock.
  29. Seymour CW., et al. “Assessment of clinical criteria for sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)”. The Journal of the American Medical Association 8 (2016): 762-774.




Citation: Abhishek Kumar Verma., et al. “Pathogenesis, Epidemiology, and Clinical Features among SARS-CoV-2 and Associated Diseases: An Editorial". Acta Scientific Pharmaceutical Sciences 4.11 (2020): 01-06.


Acceptance rate32%
Acceptance to publication20-30 days
Impact Factor0.759

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 30, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US